Literature DB >> 6214987

Pharmacokinetics of piperacillin in patients with moderate renal failure and in patients undergoing hemodialysis.

J A Giron, B R Meyers, S Z Hirschman, E Srulevitch.   

Abstract

The pharmacokinetics of piperacillin administered intravenously were studied in five patients with stable mild to moderate renal impairment and in five patients undergoing hemodialysis. Patients with stable renal failure given 1 g of piperacillin intravenously had peak serum concentrations within 30 min ranging from 78 to 280 micrograms/ml. The mean serum half-life was 3.57 +/- 1.36 h; the mean apparent volume of distribution was 28.6 +/- 13.5 liters/100 kg; and the plasma clearance was 4.10 +/- 1.46 liters/h per 1.73 m2. Neither serum half-life nor clearance correlated with serum creatinine, implying significant nonrenal elimination. Patients undergoing hemodialysis had peak serum concentrations within 30 min of 66 to 138 micrograms/ml after 1 g of piperacillin infused intravenously. During hemodialysis, the serum half-life was 3.6 +/- 2.5 h; the mean apparent volume of distribution was 26.7 +/- 16.7 liters/100 kg; and the plasma clearance was 3.28 +/- 0.76 layers/h per 1.73 m2. Mean hemodialysis clearance was 0.484 +/- 0.282 liters/h per 1.73 m2, and only 10.0 +/- 5.3% of the total dose could be recovered in the dialysate.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6214987      PMCID: PMC181409          DOI: 10.1128/AAC.19.2.279

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  9 in total

1.  Drug therapy. Clinical Pharmacokinetics (first of two parts).

Authors:  D J Greenblatt; J Kock-Weser
Journal:  N Engl J Med       Date:  1975-10-02       Impact factor: 91.245

2.  Pharmacokinetics of tobramycin in patients with stable renal impairment, patients undergoing peritoneal dialysis, and patients on chronic hemodialysis.

Authors:  G Jaffe; B R Meyers; S Z Hirschman
Journal:  Antimicrob Agents Chemother       Date:  1974-06       Impact factor: 5.191

3.  Piperacillin, a new penicillin with high anti-pseudomonal activity.

Authors:  S E Milne; P M Waterworth
Journal:  J Antimicrob Chemother       Date:  1978-05       Impact factor: 5.790

4.  Pharmacokinetics of intravenous piperacillin in patients undergoing chronic hemodialysis.

Authors:  E L Francke; G B Appel; H C Neu
Journal:  Antimicrob Agents Chemother       Date:  1979-12       Impact factor: 5.191

5.  Pharmacokinetics of piperacillin following intravenous administration.

Authors:  M A Evans; P Wilson; T Leung; J D Williams
Journal:  J Antimicrob Chemother       Date:  1978-05       Impact factor: 5.790

6.  Piperacillin, a new penicillin active against many bacteria resistant to other penicillins.

Authors:  K P Fu; H C Neu
Journal:  Antimicrob Agents Chemother       Date:  1978-03       Impact factor: 5.191

7.  Turbidimetric studies of growth inhibition of yeasts with three drugs: inquiry into inoculum-dependent susceptibility testing, time of onset of drug effect, and implications for current and newer methods.

Authors:  J N Galgiant; D A Stevens
Journal:  Antimicrob Agents Chemother       Date:  1978-02       Impact factor: 5.191

8.  Piperacillin kinetics.

Authors:  V K Batra; J A Morrison; K C Lasseter; V A Joy
Journal:  Clin Pharmacol Ther       Date:  1979-07       Impact factor: 6.875

9.  Comparative study of piperacillin, ticarcillin, and carbenicillin pharmacokinetics.

Authors:  B R Meyers; S Z Hirschman; L Strougo; E Srulevitch
Journal:  Antimicrob Agents Chemother       Date:  1980-04       Impact factor: 5.191

  9 in total
  9 in total

1.  Neurotoxicity associated with standard doses of piperacillin in an elderly patient with renal failure.

Authors:  W-T Huang; Y-J Hsu; P-L Chu; S-H Lin
Journal:  Infection       Date:  2009-06-04       Impact factor: 3.553

2.  High-performance liquid chromatographic determination of piperacillin in plasma.

Authors:  A M Brisson; J B Fourtillan
Journal:  Antimicrob Agents Chemother       Date:  1982-04       Impact factor: 5.191

3.  Pharmacokinetics of intravenous piperacillin administration in patients undergoing on-line hemodiafiltration.

Authors:  Kook-Hwan Oh; Chiweon Kim; Hankyu Lee; Hajeong Lee; Ji Yong Jung; Nam Joong Kim; Kyung-Sang Yu; Kwang-Hee Shin; In-Jin Jang; Curie Ahn
Journal:  Antimicrob Agents Chemother       Date:  2009-05-18       Impact factor: 5.191

4.  Plasma levels of piperacillin and vancomycin used as prophylaxis in liver transplant patients.

Authors:  M Dupon; G Janvier; G Vinçon; S Winnock; F Demotes-Mainard; O Capeyron; J Saric
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

5.  The effect of piperacillin dose on elimination kinetics in renal impairment.

Authors:  G R Aronoff; R S Sloan; M E Brier; F C Luft
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

6.  Optimal design of perturbations for individual two-compartment pharmacokinetic analysis.

Authors:  Matthew S Shotwell; Minchun Zhou; William H Fissell
Journal:  J Biopharm Stat       Date:  2015-08-06       Impact factor: 1.051

7.  Piperacillin pharmacokinetics in pediatric patients.

Authors:  C B Wilson; J R Koup; K E Opheim; L A Adelman; J Levy; T L Stull; C Clausen; A L Smith
Journal:  Antimicrob Agents Chemother       Date:  1982-09       Impact factor: 5.191

Review 8.  Piperacillin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  B Holmes; D M Richards; R N Brogden; R C Heel
Journal:  Drugs       Date:  1984-11       Impact factor: 9.546

Review 9.  Piperacillin-tazobactam as alternative to carbapenems for ICU patients.

Authors:  Benoit Pilmis; Vincent Jullien; Alexis Tabah; Jean-Ralph Zahar; Christian Brun-Buisson
Journal:  Ann Intensive Care       Date:  2017-11-10       Impact factor: 6.925

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.